Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan.
about
Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRIThe Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis.Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.Future treatment option for hepatocellular carcinoma: a focus on brivanib.Diagnostic imaging of hepatocellular carcinoma: recent progress.Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential.Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan.Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma.Can non-invasive assessment of liver fibrosis replace liver biopsy?Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B.Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil therapy.Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B.Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA.Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran.
P2860
Q30444857-213CEF7F-4385-4944-AB76-02476FBF3B67Q35726960-4D54F6E4-7A5C-44BD-94AD-ECCEEBD3D107Q37883147-6618759F-74E3-438B-BC0A-DCF27E1133AAQ37914624-67298F65-D31C-4E15-AFE5-4C97D0E93917Q37914636-D8C32AFF-A97B-4D00-8ED5-A6674F77039AQ37972809-9460EC62-CF1A-48CD-A741-A4BF579A399EQ38075796-E9F6DD5E-B856-44AF-BA53-0FB2BC36E488Q38083429-D9B27AA9-AF94-4922-A9DF-9AB39BED9092Q38100847-5836CCBE-40DD-41A8-B2D0-892B959DBA8FQ39298929-01BA8A22-7214-46AF-BFD1-C905262241ADQ39604877-1B144D80-EB92-400B-98FE-801752B633F4Q39677737-308D3CC4-63BF-4968-957F-73A1C08424D6Q39985036-AAD8A313-F19F-46C2-87D2-D37EBDE9DE94Q40151821-4206393F-90F4-4D22-99E2-8430400EAE65Q42174830-F49AE16F-397D-4BD9-8EE4-C142B8D26FBDQ42269927-ED0B621A-0171-474E-8F7B-32AAD13D11E0Q42283787-B1ECA010-5C6D-413A-92E8-3D681E0F7222Q43950558-D160044F-C9FF-4FD4-90A6-40505B43976FQ44082487-F5A31B60-2649-4060-B2B5-A81A484690E6Q50522258-6893CD42-C4CA-4F2C-8C89-BC61EEE3CD23Q51541140-70C95D85-F98D-410D-A430-4D52F6B0896AQ53164559-2E6DEA25-284C-485B-B904-ECC50A01EA06Q55653769-4FEEAAB2-A890-4984-8DD7-3C4C4D2C99E4
P2860
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Guidelines for the treatment o ...... the fiscal year 2008 in Japan.
@en
Guidelines for the treatment o ...... the fiscal year 2008 in Japan.
@nl
type
label
Guidelines for the treatment o ...... the fiscal year 2008 in Japan.
@en
Guidelines for the treatment o ...... the fiscal year 2008 in Japan.
@nl
prefLabel
Guidelines for the treatment o ...... the fiscal year 2008 in Japan.
@en
Guidelines for the treatment o ...... the fiscal year 2008 in Japan.
@nl
P2093
P1433
P1476
Guidelines for the treatment o ...... the fiscal year 2008 in Japan.
@en
P2093
Eiji Tanaka
Fumitaka Suzuki
Hideyuki Nomura
Hiromitsu Kumada
Hiroshi Yotsuyanagi
Hisataka Moriwaki
Joji Toyota
Kazuaki Chayama
Kentaro Yoshioka
Makoto Oketani
P356
10.1111/J.1872-034X.2009.00633.X
P577
2010-01-01T00:00:00Z